ASN001

ASN001 is an orally available, non-steroidal, and highly selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17). It acts by selectively inhibiting CYP17 lyase activity, leading to potent suppression of testosterone synthesis while sparing cortisol synthesis. This selectivity may eliminate the need for co-administration of prednisone, which is typically required with other CYP17 inhibitors. ASN001 has demonstrated high oral bioavailability and a low potential for drug-drug interactions. It was developed primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC), where it showed promising safety and efficacy in early-phase clinical trials[1][2][3][4][6].

Other names

cyp17 lyase inhibitor asn001cyp-17 lyase inhibitor asn001cyp 17 lyase inhibitor asn001